SCHEMBL4849050

SCHEMBL4849050

CCOC(=O)c1cn(Cc2ccccc2)nc1OCc1ccc(OCc2nc(-c3ccco3)oc2C)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
HSP90AA1 P07900 1/20 0.42
PPARG P37231 8/20 0.41
PPARA Q07869 8/20 0.41
MAOB P27338 1/20 0.41
ADORA3 P0DMS8 5/20 0.40
ADORA2A P29274 5/20 0.40
ADORA1 P30542 4/20 0.40
ADORA2B P29275 3/20 0.40
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5381940 0.98 FFAR1 (0.41) FFAR1KMT2AMEN1HSP90AA1PPARG
SCHEMBL4851267 0.93 FFAR1 (0.46) FFAR1KMT2APPARGPPARAADORA3
SCHEMBL4852293 0.93 KDR (0.45) KMT2AMEN1HSP90AA1PPARGPPARA
SCHEMBL4846728 0.92 PPARG (0.43) KMT2AMEN1HSP90AA1PPARGPPARA
SCHEMBL5397282 0.91 FFAR1 (0.45) FFAR1KMT2APPARGPPARAADORA3
SCHEMBL4852404 0.91 FFAR1 (0.44) FFAR1KMT2APPARGPPARAADORA3
SCHEMBL4854276 0.90 ADORA3 (0.40) PPARGPPARAADORA3ADORA2AADORA1
SCHEMBL4851691 0.90 FFAR1 (0.54) FFAR1KMT2AMEN1HSP90AA1PPARG
SCHEMBL4852926 0.90 PPARG (0.43) KMT2AMEN1PPARGPPARAADORA3
SCHEMBL4853530 0.90 PPARG (0.40) KMT2AMEN1PPARGPPARAADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 FFAR1 771/4885KMT2A 1792/4885MEN1 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.